X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Based on research from Håvard Attramadal's lab at Oslo University Hospital, Tribune is developing a novel drug with a pan-antifibrotic mechanism of action targeting several fibrotic indications including diseases affecting the kidney, lung and liver.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Tribune Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing June 02, 2021
Details:
The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.
Lead Product(s): Emactuzumab
Therapeutic Area: Oncology Product Name: CXD301
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: SynOx Therapeutics
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
